Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7775162 | 0.84 | SCN9A (0.40) | SCN9AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20505832 | 0.82 | SLC6A4 (0.36) | SCN9AKDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL29402339 | 0.78 | TSHR (0.43) | SCN9AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5699178 | 0.78 | SCN9A (0.33) | SCN9AKDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL22366611 | 0.78 | TSHR (0.43) | SCN9AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30079497 | 0.78 | SCN9A (0.33) | SCN9AKDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL30695904 | 0.75 | SCN9A (0.36) | SCN9AKDM4EMAPTCRHBPCRHR2 | |
| SCHEMBL23043168 | 0.75 | SCN9A (0.36) | SCN9AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL900045 | 0.75 | SCN9A (0.42) | SCN9AALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL900047 | 0.75 | ACHE (0.44) | SCN9ASLC6A2SLC6A4CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958865-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4225445-A2 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3958865-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020216774-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| EP-3700904-A1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | Bayer AG (DE) | 2020-09-02 | — | — | EP | disclosed |
| EP-1031555-B1 | DIFLUOROMETHOXYBENZENE DERIVATIVES AND THEIR USE AS INTERMEDIATES | IHARA CHEMICAL IND CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| EP-0878194-A1 | REMEDIES OR PREVENTIVES FOR AIDS | SANKYO COMPANY LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5688791-A | COMPOUNDS FOR TREATMENNT OF VIRAL DISEASES SUCH AS AIDS | UBE INDUSTRIES, LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5519016-A | Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent | UBE INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | disclosed |
| EP-0572259-A1 | Aminoquinolone derivatives as anti-HIV agents | UBE INDUSTRIES, LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | SCN9A 4319/4885KDM4E 3981/4885MAPT 1075/4885 |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | SCN9A 3882/4885KDM4E 4216/4885MAPT 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.